Investing.com - Intensity Therapeutics (NASDAQ: INTS) reported third quarter EPS of $-0.17, $0.08 worse than the analyst estimate of $-0.09. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.00.
Intensity Therapeutics's stock price closed at $2.72. It is down -53.66% in the last 3 months and up 0.00% in the last 12 months.
Intensity Therapeutics saw positive EPS revisions and negative EPS revisions in the last 90 days. See Intensity Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Intensity Therapeutics's Financial Health score is "fair performance".
Check out Intensity Therapeutics's recent earnings performance, and Intensity Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar